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Introduction
Gene silencing by miRNAs is primarily achieved by targeting the
3 untranslated region (UTR) of mRNAs and induces translational
silencing, either by cleaving and degrading the target mRNA or
blocking ribosomal translation of the targeted mRNA (Pillai et al.,
2007), although examples of miRNAs targeting coding regions have
recently been described (Forman et al., 2008; Grimson et al., 2007).
miRNAs have been shown to be expressed in a lineage-specific
manner both in normal development (Hino et al., 2008; Ramkissoon
et al., 2006) and cancer (Blenkiron et al., 2007; Gaur et al., 2007;
Mattie et al., 2006; Sempere et al., 2007).
The mammary gland consists of two distinct cell lineages, basal
and lumenal, which together form the ductal mammary epithelium.
Many studies have provided evidence for a common bipotent
progenitor that gives rise to ductal lumenal, alveolar lumenal and
myoepithelial (basal) cells. However, the molecular mechanisms
that regulate lineage commitment at each stage of mammary-gland
development remain ill-defined (reviewed by Wagner and Smith,
2005). In the present study, the COMMA-DbGeo cell line was used
as an in vitro model system to study adult mammary stem or
progenitor cells. This cell line was originally derived from mammary
epithelium isolated from midpregnant Balb/c mice (Campbell et
al., 1988; Danielson et al., 1984). COMMA-DbGeo cells consist
of a heterogeneous population of cells, including a subpopulation
enriched for putative progenitor-like cells as defined by the
expression of stem cell antigen 1 (Sca-1; encoded by Ly6a). Sca-
1, originally identified as a marker of hematopoietic stem cells
(Spangrude et al., 1988), has been used to identify mammary-gland
progenitor cells (Welm et al., 2002), as well as a variety of stem
or progenitor cells in other tissues, including skin (Montanaro et
al., 2003), muscle (Torrente et al., 2001) and testis (Falciatori et
al., 2004; Xin et al., 2005). More recently, it has been suggested
that, in the normal mammary gland, lumenal Sca-1-positive (Sca-
1+) cells are estrogen-receptor positive, and, although most of these
are terminally differentiated, there is a subset that might be lumenal
progenitors (Sleeman et al., 2007; Stingl, 2009).
The Sca-1+ and Sca-1– cell populations of COMMA-DbGeo
display different morphogenic phenotypes and growth potentials,
in both in vitro clonogenic assays and in vivo mammary-gland
repopulation assays. The Sca-1+ subpopulation displays an
undifferentiated basal phenotype, on the basis of staining negative
for lumenal cytokeratins (K) K8 and K18, positive for basal
cytokeratins K5 and K14, and negative for myoepithelial a-smooth-
muscle actin (Deugnier et al., 2006). When transplanted into the
cleared fat pad of the mouse mammary gland, the Sca-1+ population
gives rise to branched ductal epithelium containing lumenal and
myoepithelial cells, whereas the Sca-1– population displays a
reduced outgrowth potential (Deugnier et al., 2006; Welm et al.,
2002). In addition, Sca-1+ cells form colonies when plated on
Matrigel, whereas the same number of Sca-1– cells fail to do so
(Chen et al., 2007; Woodward et al., 2007). This clonogenicity is
reflective of the self-renewal potential of Sca-1+ cells. Sca-1+ cells
will also give rise to both Sca-1+ and Sca-1– cells when grown in
culture, which is indicative of their multipotency (Chen et al.,
2007).
The COMMA-DbGeo cell line was used as representative of
mammary-gland progenitor cells to identify miRNAs that might be
important in lineage determination during mammary-gland
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Summary
In an effort to understand the potential role of microRNAs (miRNAs) in mammary-gland stem or progenitor cells, miRNA microarrays
were performed on subpopulations of the mouse mammary epithelial cell (MEC) line COMMA-DbGeo. This cell line contains a
heterogeneous subpopulation of progenitors characterized by the expression of stem cell antigen 1 (Sca-1; encoded by Ly6a). Microarray
analysis indicated that the Sca-1 subpopulations have distinct miRNA expression profiles. Functional studies were performed on miR-
205, which was highly expressed in the Sca-1-positive (Sca-1+) cells. When miR-205 was overexpressed in vitro, the COMMA-DbGeo
cells underwent several significant morphological and molecular changes. miR-205 overexpression led to an expansion of the progenitor-
cell population, decreased cell size and increased cellular proliferation. In addition, the colony-forming potential of the two Sca-1
subpopulations was increased. Target prediction for miR-205 indicated that it might regulate the expression of the tumor-suppressor
protein PTEN. Overexpression studies using reporter constructs confirmed that PTEN expression is regulated by miR-205. In addition
to PTEN, several other putative and previously validated miR-205 targets were identified by microarray analysis, including the previously
reported miR-205 targets ZEB1 and ZEB2. Additionally, in normal mouse MECs, high expression of miR-205 was observed in stem-
cell-enriched cell populations isolated by FACS using established cell-surface markers.











607miR-205 in mammary progenitors
development. We observed discrete miRNA expression profiles in
these different Sca-1 subpopulations. We focused our studies on
miR-205, which was observed to be the most highly upregulated
miRNA in the Sca-1+ population as compared with the Sca-1–
population. We used the well-characterized phenotypes attributed
to the Sca-1+ and Sca-1– cells to assess the effect of overexpression
of miR-205. We demonstrated that this miRNA targets the
previously reported regulators of epithelial-mesenchymal transition
(EMT) ZEB1 and ZEB2, as well as several targets not previously
described, including the Na+-K+ transporter Atp1a1, the docking
protein Dok4 and the tumor-suppressor gene phosphatase and tensin
homolog (PTEN). In addition, when miR-205 was overexpressed,
we observed changes in replicative competence, cell size, cell
proliferation and the percentage of progenitor-cell populations.
Finally, miR-205 was shown to be selectively upregulated in stem
and/or progenitor cells isolated from normal MECs using FACS
and established cell-surface markers, demonstrating the relevance
of using the COMMA-DbGeo model.
Results
The Sca-1 subpopulations of the COMMA-DbGeo cell line
express a distinct set of miRNAs
The COMMA-DbGeo cell line maintains a heterogeneous
population of cells, on the basis of the presence or absence of the
cell-surface marker Sca-1; presence of this marker can easily be
distinguished by FACS (Fig. 1A). This cell line typically retains
between 13-20% Sca-1+ cells in culture: Sca-1+ cells are
characterized as multipotent progenitor cells by in vitro and in vivo
assays (Chen et al., 2007; Deugnier et al., 2006). Because Sca-1+
and Sca-1– cells are functionally different, we sought to identify
differentially expressed miRNAs between the two cell populations
using miRNA microarrays (Fig. 1B). Two different miRNA
microarray platforms were used (custom microarrays and Paraflo
microarrays), revealing a consistent set of differentially expressed
miRNAs. Results from both microarray platforms were analyzed
for fold change and compared. A set of 15 upregulated miRNAs
and six downregulated miRNAs between the two populations of
cells were consistently observed (Table 1). Array data for several
miRNAs were subsequently verified by quantitative real-time
reverse-transcriptase (RT)-PCR (qPCR) and fold change was
confirmed (Fig. 1C; supplementary material Fig. S1A-C).
Microarray data revealed that miR-205 was the most upregulated
miRNA in the Sca-1+ cells and this expression was verified by qPCR
(Fig. 1C). This miRNA has been shown to be upregulated in non-
metastatic human breast cancers (Iorio et al., 2005); however, until
very recently, very little was known about the function or targets
of this miRNA. Interestingly, a recent study also observed high
expression of miR-205 in a different progenitor-cell population of
the COMMA-DbGeo cell line using a cloning method (Ibarra et
al., 2007), although Aldefluor, the method they employed for
isolating progenitor cells in the mouse, has yet to be functionally
validated in vivo. In addition to miR-205, Ibarra et al. also detected
several of the same miRNAs in the Aldefluorhi/Sca-hi population
that we observed to be highly expressed in the Sca-1+ cells, miR-
21, miR-22 and miR-31, indicating that these two populations, Sca-
1+ and Aldefluorhi/Sca-1hi, might partially overlap.
Mouse miR-205 affects the progenitor-cell compartment,
cell size and proliferation
To determine whether miR-205 plays a functional role in the
progenitor-cell population of COMMA-DbGeo cells, we first
overexpressed it using the pSM2 retroviral vector. Under the pSM2
U6 promoter, miR-205 expression was increased between two- to
fourfold over the levels observed in cells transduced with the
luciferase shRNA negative control vector in the COMMA-DbGeo
cells. When further separated into the Sca-1 subpopulations, we
found that miR-205 levels in Sca-1+ cells were approximately
twofold higher than the luciferase shRNA cells. Whereas the Sca-
1– cells did not obtain the high levels of miR-205 expression
observed in the Sca-1+ cells, expression of miR-205 was increased
nearly fivefold in the Sca-1– population when transduced with the
Fig 1. Identification of miRNAs differentially expressed in the Sca-1
subpopulations of the COMMA-DbGeo cell line. (A)Representative FACS
histogram showing Sca-1 expression in COMMA-DbGeo cells. Cells stained
with a FITC-conjugated antibody against Sca-1 analyzed by FACS display two
distinct populations based on Sca-1–FITC fluorescence: 17% are Sca-1+ and
60.2% are Sca-1–. Shown are 75,000 events. (B)Representative heat map
showing the differential expression of miRNAs in the Sca-1+ and Sca-1–
subpopulations. Each row represents a different mature miRNA sequence.
Shown are median values from normalized, log-ratio (base 2) data sets and
plotted as a heat map from two biological and technical replicates. Yellow
indicates high miRNA expression; blue indicates low miRNA expression.
Differentially expressed miRNAs are detailed in Table 1 from three
independent microarray experiments performed on three biological replicates
each. Expression values produced a cladogram reflecting a clear distinction
between the Sca-1+ and Sca-1– cells. The red arrow indicates the location of
miR-205 on the array, where the average fold change was 6.56 higher in the
Sca-1+ cells versus Sca-1–. (C)TaqMan qPCR of miR-205 verify the
microarray data. miR-205 is approximately 19-fold higher in the Sca-1+
population compared with the Sca-1– population. Data represent the mean
expression levels of two different biological replicates calculated by CT
normalized to the endogenous snoRNA55 control, of two independent












pSM2–miR-205 vector as compared to the luciferase shRNA
control (supplementary material Fig. S1D). In cells overexpressing
miR-205, we observed a significant expansion of the Sca-1+ cell
population, on the basis of FACS analysis for Sca-1–FITC,
compared with the luciferase shRNA control (Fig. 2A,B). Typically,
an increase from the expected 13-20% of Sca-1+ cells to 39-53%
was observed following overexpression of miR-205.
In addition to the expansion of the progenitor-cell compartment,
overexpression of miR-205 resulted in a significantly smaller cell
size as compared with the luciferase shRNA control cells (Fig. 2C,D).
Results are expressed as percentage change in forward scatter (FSC)
compared with the luciferase shRNA cells. The total population of
viable cells decreased in size by approximately 4-5% when
overexpressing miR-205. Because Sca-1– cells are generally smaller
than Sca-1+ cells, these differences were further highlighted when
cells were separated into the two Sca-1 subpopulations. Sca-1+ cells
were 6-7% smaller, and Sca-1– cells were 8-9% smaller, when
overexpressing miR-205 compared with the Sca-1+ and Sca-1–
luciferase shRNA control cells, respectively (Fig. 2D).
Overexpression of miR-205 also led to increased cell proliferation
both in growth-curve (Fig. 2E) and cell-proliferation (Fig. 2F) assays.
When plated at the same density and growth conditions, miR-205-
overexpressing cells proliferated at a significantly higher rate for 6
days (P<0.0001) than the luciferase shRNA control cells in a growth-
curve assay. Similarly, in a cell-proliferation assay, cells
overexpressing miR-205 continued to proliferate at a significantly
(P<0.005) higher rate once cell density reached confluency, in contrast
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to the luciferase shRNA control cells, that exhibited contact-mediated
growth inhibition. These results suggest that miR-205 regulates the
self-renewal and/or proliferation of Sca-1+ progenitor cells.
Overexpression of miR-205 changes the colony-forming
potential of Sca-1+ and Sca-1– cells
Sca-1+ COMMA-DbGeo cells are capable of forming colonies when
plated on Matrigel, whereas Sca-1– cells are unable to do so (Chen
et al., 2007; Deugnier et al., 2006; Woodward et al., 2007). As a
measure of replicative competence, colony-forming assays were
performed on miR-205-overexpressing cells. Sca-1+ cells
overexpressing miR-205 formed significantly more colonies than
control cells (Fig. 3A). Interestingly, whereas normal Sca-1– cells
lack the ability to form colonies on Matrigel, they gained the ability
to form colonies on Matrigel when overexpressing miR-205 (Fig.
3B). Representative images of both the Sca-1+ and Sca-1– colony-
forming assays are shown in Fig. 3C.
In addition to changes in colony-forming ability, Sca-1+ colonies
formed from miR-205-overexpressing cells were larger than
colonies formed from the luciferase shRNA control cells
(P<0.0005). Furthermore, Sca-1+ colonies formed from miR-205-
overexpressing cells were composed of more cells than the luciferase
shRNA cells. Fewer cells overall contribute to the Sca-1– miR-205
colonies, accounting for their smaller size (data not shown). These
changes in Sca-1+ colony size are probably attributed to the increase
in proliferation that was observed in the miR-205-overexpressing
cells.





(P 0.05) Association with human breast cancer
miR-205 6.58 F non-metastatic BC (Iorio et al., 2005); F ER+, PR+ and ErbB2+ BC (Mattie et al., 2006); f BC compared with normal breast
(Volinia et al., 2006); within a genomically amplified region in BC (Blenkiron et al., 2007)
miR-29b† 3.78 F ER+ and PR+ BC and f invasive BC (Iorio et al., 2005); F BC compared with normal breast (Volinia et al., 2006)
miR-143 3.42 F ER+, PR+ and ErbB2+ BC (Mattie et al., 2006)
miR-145 3.41 F BC with low proliferation (Iorio et al., 2005); F ER+, PR+ and ErbB2+ BC (Mattie et al., 2006); f BC compared with normal
breast (Volinia et al., 2006); F ER+ luminal A subtypes, lower grade tumors and normal tissue (Blenkiron et al., 2007)
miR-31 3.40 F BC tissue compared with normal breast tissue (Volinia et al., 2006)
miR-29a 3.37 F non-metastatic BC (Iorio et al., 2005); F ER+, PR+ and ErbB2+ BC (Mattie et al., 2006); F BC compared with normal breast
(Volinia et al., 2006); within a genomically amplified region in BC (Blenkiron et al., 2007)
miR-27a 3.35 F non-metastatic BC (Iorio et al., 2005); F in PR+ and ErbB2+ BC (Mattie et al., 2006)
miR-21 3.33 F stage pT2-3 compared with earlier stage BC (Iorio et al., 2005); F ER+, PR+ and ErbB2+ BC (Mattie et al., 2006); F BC
compared with normal breast (Volinia et al., 2006); within a genomically amplified region in BC (Blenkiron et al., 2007)
miR-210 3.18 F ER+ BC (Mattie et al., 2006); F BC compared with normal breast (Volinia et al., 2006)
miR-27b 3.10 F ER+, PR+ and ErbB2+ BC (Mattie et al., 2006)
miR-292-5p 2.92 Within the stem-cell-specific miR-290 cluster that controls DNA methylation and telomere recombination via Rbl2-dependent
regulation of DNA methyltransferases (Benetti et al., 2008)
miR-22 2.91 F ER+, PR+ and ErbB2+ BC (Mattie et al., 2006)
miR-96 1.86 Within a genomically amplified region in BC (Blenkiron et al., 2007)
miR-377 –9.35 Within a miRNA cluster at the Dlk1-Gtl2 domain that is epigenetically silenced in epithelial cancers (Zhang et al., 2008a)
miR-200b –3.39 Within a region associated with genomic loss in BC (Blenkiron et al., 2007)
miR-148† –3.07 F ER+ and PR+ BC (Mattie et al., 2006); located near the HOXC cluster, a potential site for disregulation in cancer (Calin et al.,
2004); within a genomically amplified region in BC (Blenkiron et al., 2007)
miR-34a –2.82 F PR+ BC (Mattie et al., 2006); within a deleted region associated with BC (Calin et al., 2004; Gupta et al., 2005)
miR-489 –2.80 Suppressor of metastasis and decreased in metastatic BC (Tavazoie et al., 2008)
miR-203 –2.50 F advanced stage compared with earlier stage BC (Iorio et al., 2005)
Data from microarray analysis of mouse miRNA expression. Microarray analysis was used to identify miRNAs with differential expression between the
Sca-1 populations of the COMMA-D Geo cell line. miRNAs with a statistically significant (P 0.05) fold change in expression from three separate microarrays
are listed. Fold change is the change in expression in Sca-1+ population relative to the Sca-1– population. BC, breast cancer; ER, estrogen receptor; PR,
progesterone receptor.
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Mouse miR-205 targets the tumor-suppressor gene PTEN
To elucidate potential targets of miR-205, we performed
computational analysis using all available target prediction algorithms.
Several computational algorithms exist for the prediction of miRNA
targets (reviewed by Rajewsky and Socci, 2004), but often these
algorithms will predict different targets for the same miRNA.
PTEN was identified as a predicted target of miR-205 by the
miRanda algorithm at the miRNA Viewer website
(http://cbio.mskcc.org/mirnaviewer/). The miRanda algorithm
predicts two putative miR-205-binding sites in the coding region of
the PTEN mRNA. By other computational analyses, there were also
two predicted miR-205-binding sites in the PTEN 3UTR (Fig. 4A).
To determine whether miR-205 regulates PTEN expression via
the 3UTR, we cloned the PTEN 3UTR from a wild-type Balb/c
mouse into the 3UTR of a luciferase reporter (Fig. 4A). We used
NIH/3T3 cells to overexpress miR-205 using the pSM2 vector,
routinely obtaining miR-205 expression that was 20- to 30-fold
higher, and in some cases up to 120-fold higher in some clones, as
compared with cells transduced with the pSM2-non-silencing
hairpin control or the pSM2-luciferase shRNA control
(supplementary material Fig. S1E). Additionally, when the
pmiRZip-205 anti-miRNA expression vector was transduced into
NIH/3T3 cells, we were able to obtain an approximate five- to
sixfold decrease in miR-205 expression compared with the
pmiRZip-luciferase shRNA control (supplementary material Fig.
S1F). We observed a statistically significant decrease (P<0.01) in
luciferase reporter activity when cells overexpressed miR-205
compared with cells that expressed the non-silencing hairpin control
(Fig. 4B). As expected, decreased reporter activity was observed
in the cells expressing the luciferase shRNA (positive control). In
the reciprocal experiment, when cells expressed the pmiRZip-205
miRNA inhibitor, we observed a significant increase (P<0.0005)
in luciferase reporter activity compared with cells that expressed
the non-silencing hairpin control (Fig. 4C).
Fig 2. Overexpression of miR-205 affects cell size, cell proliferation and expands the progenitor-cell compartment. (A)Representative FACS analysis of
COMMA-DbGeo cells indicates that overexpression of miR-205 expands the Sca-1+ percentage compared with cells expressing the luciferase shRNA control.
Cells were sorted for Sca-1–FITC and separated into Sca-1+ and Sca-1– cells. Shown are 25,000 events. (B)Quantitation of the percent of cells that are either Sca-
1+ or Sca-1– based on FACS analysis. Populations that overexpress miR-205 (white bars) have more Sca-1+ cells compared with populations expressing the
luciferase shRNA control (black bars). ***P<0.001; **P<0.01. (C)COMMA-DbGeo cells overexpressing miR-205 are smaller than cells expressing the control
luciferase shRNA as determined by FACS analysis. Cells were sorted for Sca-1–FITC and separated into Sca-1+ and Sca-1– cells. In all three compartments – total
(viable) cells, Sca-1+ and Sca-1– – miR-205-overexpressing cells are all smaller than the luciferase shRNA cells. Shown are 25,000 events. (D)Quantitation of
mean FSC percent, which is proportional to cell size, based on FACS analysis. miR-205-overexpressing cells (white bars) are significantly smaller in the Sca-1+
and Sca-1– cell populations compared with cells expressing the luciferase shRNA control (black bars). Cell size is given in percentage relative to the control, set at
100%. *P<0.05; **P<0.005. (E)Growth curves of miR-205-overexpressing cells and luciferase shRNA cells. Cells were plated at the same density and counted
every 24 hours for 6 days (shown are timepoints up to 96 hours). Cells overexpressing miR-205 are proliferating at significantly higher rates than the control. At
144 hours post-plating, there are still significantly more miR-205-overexpressing cells (P<0.0001) compared with the luciferase shRNA cells (not shown).
***P<0.0001 compared with luciferase shRNA. (F)Cell-proliferation assay, where percent dividing cells represents the fraction of cells that are or have
synthesized DNA in preparation for cell division (equivalent to the sum of the percentages of cells in S+G2-M), as determined by the Click-iT EdU Flow
Cytometry Assay. Cells overexpressing miR-205 have significantly higher proliferation rates (P<0.005) compared with the luciferase shRNA cells. All data












Relative to the start of the PTEN 3UTR, one miR-205-binding
site was predicted at nucleotides 559-585 by a site prediction
algorithm, STarMir (Long et al., 2008), as well as at nucleotides
732-764, which was predicted by MicroInspector (Rusinov et al.,
2005). To further validate these miR-205 seed sites in the 3UTR,
we mutated these computationally predicted target sites in the
miRNA-binding seed regions (nucleotides in red in Fig. 4A), to
prevent miRNA binding. Accordingly, when either miR-205-
binding site was mutated, we observed a relief of silencing of the
reporter gene, suggesting that these are probably true miR-205 target
sites (Fig. 4D).
For confirmation of PTEN expression at the protein level,
western blot analysis was performed on protein extracts from
COMMA-DbGeo cells transduced with the miR-205 overexpression
vectors along with cells expressing an shRNA against PTEN as a
positive control. These results showed a slight reduction in PTEN
expression when miR-205 was overexpressed as compared with the
luciferase shRNA control vector (Fig. 4E). This reduction in PTEN
protein level was also correlated with increased phosphorylation of
glycogen synthase kinase-3b (GSK-3b) at serine 9, one of the
functional downstream PI3K-AKT substrates (Fig. 4E). This
phosphorylation of the inhibitory N-terminal serine is mediated in
part by the active AKT kinase. PTEN mRNA levels were also
determined by qPCR. As in the western blot analysis, when miR-
205 was overexpressed, PTEN mRNA levels decreased by
approximately 50% as compared with the luciferase shRNA control
(Fig. 4F). Collectively, these results indicate that miR-205 regulates
PTEN expression.
Mouse miR-205 has many predicted and non-predicted
targets
Because knockdown of PTEN did not completely recapitulate the
miR-205-overexpression phenotype (data not shown), we sought
to identify other targets of miR-205. If all available algorithms are
Journal of Cell Science 123 (4)
taken into consideration, miR-205 can potentially target over 2000
genes. To determine the efficiency of miR-205 to target other
mRNAs genome-wide, we performed a gene-chip analysis of miR-
205-overexpressing COMMA-DbGeo cells. Of the ~45,000 probe
sets represented on the Affymetrix Mouse Genome 430 2.0 array,
344 unique transcripts were decreased in cells overexpressing miR-
205 compared with those expressing the luciferase shRNA control
(using the criterion of >1.25-fold downregulation with P<0.01). Of
these 344 transcripts, only 45 (13%) were identified by target
prediction algorithms, most of which are directed at the 3UTR.
This is not totally unexpected because not all of the 344 mRNAs
were anticipated to be direct primary miR-205 targets. Additionally,
it was previously noted that target prediction algorithms accounted
for only one-third of the actual targets revealed in proteomic analysis
of a mouse knockout model (Baek et al., 2008), suggesting that
there are probably primary targets not indicated by prediction
algorithms as well as secondary effects. Table 2 lists the top 20
predicted targets of miR-205 with the fold change shown relative
to the luciferase shRNA control, and target prediction algorithm.
Supplementary material Table S1 lists all genes that were
downregulated by miR-205 overexpression. Several predicted (Fig.
5A-D) and non-predicted (Fig. 5G-I) targets of miR-205 were
confirmed by qPCR.
One gene verified by qPCR was Atp1a1 (Fig. 5A). Atp1a1, a
Na+-K+-transporting ATPase, was predicted to be a miR-205 target
by two algorithms, miRNAMap and miRNA Viewer. By array
analysis, Atp1a1 expression was downregulated 1.8-fold in cells
overexpressing miR-205, but this seems to be an underestimate
because, by qPCR, an approximate fourfold change was detected,
as compared with luciferase shRNA cells. As a Na+-K+ pump,
Atp1a1 is responsible for detecting and maintaining ion gradients
across the plasma membrane. Interestingly, colorectal tumors have
been shown to have decreased levels of Atp1a1 (Cao et al., 1997)
and also frequently overexpress miR-205 (Jiang et al., 2005).
Fig 3. Overexpression of miR-205 increases the colony-
forming capacity of Sca-1– COMMA-bGeo cells.
COMMA-bGeo cells transduced with the pSM2 miRNA
overexpression vectors were sorted into Sca-1+ and Sca-1–
populations. (A)Left y-axis: fold change of Sca-1+
colonies compared with the luciferase shRNA control.
Right y-axis: number of colonies formed. When
overexpressing miR-205, the clonogenic potential of the
Sca-1+ COMMA-bGeo significantly increases.
**P<0.0001. (B)Left y-axis: fold change of Sca-1–
colonies compared with the luciferase shRNA control.
Right y-axis: average number of colonies formed. When
Sca-1– cells overexpress miR-205 they gain significant
potential to form colonies when normally they could not.
**P<0.0001. (C)Representative images of colonies
formed on Matrigel when sorted for Sca-1. Scale bars:
100m. Arrows highlight colonies formed. (D)Average
area of colonies formed by Sca-1+ cells. Colonies were
measured using Image-Pro Plus (Media Cybernetics). The
average colony area formed from Sca-1+ cells
overexpressing miR-205 were statistically larger than
those formed from the luciferase shRNA control cells. An
average of 130 colonies measured from each group were
measured. ***P<0.0005. Data represent the mean of three
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We also detected a 1.5-fold decrease of docking protein 4 (Dok4)
expression by qPCR (Fig. 5B), although array analysis indicated
that Dok4 was downregulated to a slightly greater extent (2.2-fold)
by miR-205. Dok4 is one of the most frequently predicted targets
of miR-205, predicted by five different target prediction algorithms:
MicroT, miRNA Viewer, PicTar, TargetScan and TargetRank. Dok4,
and other Dok-family members, are downstream of several tyrosine
kinases and are substrates of insulin and insulin-like growth factor
(IGF)-1 receptors (Cai et al., 2003). Insulin and IGFs are required
for the survival of normal MECs and for growth-factor-induced
cellular differentiation. Activation of IGFs in breast cancer cell lines
induces cellular proliferation and inhibits apoptosis, and it has been
shown that insulin and IGFs signal through PI3K to regulate PTEN
expression (Moorehead et al., 2003).
Not surprisingly, one of the previously confirmed targets of miR-
205 to date, ZEB2, also known as SIP1 (Gregory et al., 2008), was
identified in our array analysis as being downregulated 2.4-fold,
and was a predicted miR-205 target by five algorithms: miRNAMap,
miRNA Viewer, MicroT, PicTar, TargetRank and TargetScan.
Gregory et al. found that miR-205 was downregulated in cells that
have undergone an epithelial-to-mesenchymal transition (EMT), a
key process in embryonic development as well as in tumor
metastasis in response to growth factors. These authors also reported
that miR-205 regulates EMT by silencing ZEB2, a repressor of E-
cadherin and regulator of EMT. Accordingly, ZEB2 expression was
subsequently verified by qPCR in our miR-205-overexpressing cells
as being approximately twofold higher in the luciferase shRNA
controls as compared with the miR-205-overexpressing cells (Fig.
5C). Gregory et al. also identified ZEB1 as a miR-205 target
(Gregory et al., 2008). We therefore determined the expression levels
of ZEB1 by qPCR on the miR-205 overexpression cells. Although
the change in expression of ZEB1 was not determined to be
significant by array analysis in our assay, expression did decrease
by approximately 50% when miR-205 was overexpressed (Fig. 5D).
Endogenous expression of ZEB1 was quite low, however, in our
COMMA-DbGeo cells. As expected, expression of E-cadherin
Fig 4. miR-205 targets the mRNA of the tumor-suppressor protein PTEN. (A)Representation of the pGL3-PTEN 3UTR reporter plasmid. Shown are the
computationally predicted binding sites for mmu-miR-205 in the PTEN 3UTR (red arrowheads). Mutations were made to the seed region of the miR-205-binding
sites to disrupt miRNA-target binding (mutated nucleotides shown in red). (B)Luciferase reporter activity of the PTEN 3UTR in NIH/3T3 cells expressing miR-
205, the non-silencing hairpin negative control or the luciferase shRNA positive control. Reporter activity decreases by 30% when cells are overexpressing miR-
205. Each sample was normalized to Renilla luciferase activity. *P<0.01 or **P<0.005 relative to the non-silencing hairpin. RLU, relative luciferase units (firefly
luciferase/Renilla luciferase). (C)PTEN 3UTR reporter activity of the in NIH/3T3 cells expressing the miR-205Zipper, the non-silencing hairpin negative control
or the luiferaseZipper control. When expressing the miR-205Zipper, reporter activity increases 2.5-fold relative to the non-silencing control. Each sample was
normalized to Renilla luciferase activity. ***P<0.0005 relative to the non-silencing hairpin. (D)The computationally predicted miR-205-binding sites in the PTEN
3UTR were mutated in the seed region. Single seed-region mutations in the 559 and 732 sites significantly relieved silencing of the reporter. *P0.013 or
**P0.0057. Results are representative of four individual experiments with two biological replicates for each overexpression cell line. (E, left) Western blot
analysis of PTEN, phospho-GSK-3b (Ser9) and total GSK-3b levels in COMMA-DbGeo cells transduced with pSM2 miRNA overexpression vectors. When
overexpressing either miR-205 or the PTEN shRNA, PTEN expression levels decrease compared to luciferase shRNA control. The blot was stripped and reprobed
with b-actin as a loading control. (E, right) Levels of phospho-GSK-3b increase as a result of lowered PTEN levels when cells are overexpressing miR-205,
compared with the luciferase shRNA control. The blot was stripped and reprobed with GAPDH as a loading control. Quantitation of relative expression levels of
PTEN to b-actin and phospho-GSK-3b to total GSK-3b were determined with ImageJ. (F)TaqMan qPCR of PTEN expression. PTEN expression decreases
approximately twofold when miR-205 is overexpressed, as well as when the PTEN shRNA is expressed, relative to the luciferase shRNA control. Data represent












increased nearly 2.5-fold following miR-205 overexpression and
the subsequent decrease of both ZEB1 and ZEB2 (Fig. 5E). We
also detected by immunofluorescence a dramatic increase in cells
expressing E-cadherin as a result of miR-205 overexpression (Fig.
5F). When initially plated in cell culture conditions, these epithelial
cells typically express vimentin until the culture reaches confluency.
E-cadherin expression was observed at cell-cell junctions in the
luciferase shRNA cells, but at markedly lower levels than those
detected in miR-205-overexpressing cells. Morphologically, more
cells overexpressing miR-205 seem to have the round epithelial cell
shape than the spindle-shaped luciferase shRNA cells.
We also determined, by array analysis, the expression levels of
several non-predicted genes that were downregulated by miR-205
overexpression (Fig. 5G-I). Expressions of Six5, Ppp2r4 and Tcp1
were all downregulated by miR-205 in our array analysis. We
detected a sevenfold decrease by qPCR of Six5, a sine oculis-related
homeobox homolog, in miR-205-overexpressing cells (Fig. 5G).
A fivefold decrease in the expression of Ppp2r4, a
serine/threonine phosphatase, was detected in miR-205-
overexpressing cells by qPCR (Fig. 5H). Ppp2r4 has been shown
to have competing effects on the MAPK and AKT pathways. Ppp2r4
dephosphorylates AKT, which should inhibit the AKT pathway
(Ivaska et al., 2002). It also dephosphorylates Raf, which should
result in activation of the MAPK pathway (Dhillon et al., 2002).
Thus, it is conceivable that downregulation of Ppp2r4, in addition
to PTEN, might in part account for the increased growth and cell
survival of miR-205-overexpressing cells.
In miR-205-overexpressing cells, we observed a twofold decrease
by qPCR of Tcp1 expression (Fig. 5I). Tcp1, a T-complex protein,
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has been shown to be upregulated in mammary-gland cells as a
result of lactogenic hormone-stimulated differentiation (Desrivieres
et al., 2003), so downregulation of Tcp1 might also account for the
less differentiated phenotype that we observe in miR-205-
overexpressing cells.
To understand the mechanisms involved in miR-205
overexpression, we performed gene-set enrichment assays (GSEA)
on microarray expression profiles from the GSEA molecular
signature database website (http://www.broad.mit.edu/gsea/msigdb/
msigdb_index.html). Consistent with the hypothesis that forced
miR-205 expression might be causing cells to assume more
progenitor-cell-like properties (i.e. expansion in the progenitor-cell
compartment, decreased cell size and increased cell proliferation),
many downregulated genes overlapped with GSEA gene sets
associated with hematopoietic stem cells (RUTELLA_HEMATO -
GFSNDCS_DIFF), stromal stem cells (BOQUEST_CD31 -
PLUS_VS_CD31MINUS_DN) and genes downregulated in
differentiation pathways (BRUNO_IL3_DN) (GSEA gene sets are
indicated in supplementary material Table S1). Additionally,
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, Redwood,
CA) was used to identify biological pathways, networks and
functions significantly altered by miR-205 overexpression. The
genes identified by array analysis are classified by the IPA software
into a variety of biological processes, including cellular growth and
proliferation, cell death, cellular development, cancer, cell
morphology, and DNA replication, recombination and repair,
implying a diverse repertoire of miR-205 targets. The six most
significant molecular and cellular processes affected by miR-205
identified by IPA are shown in supplementary material Fig. S2.
Table 2. The top 20 predicted target genes downregulated by miR-205
Gene name Gene symbol Fold decrease Prediction algorithm
UDP glucuronosyltransferase 1 family, polypeptide A1 Ugt1a1 3.03 TR
Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin)
3B
Sema3b 2.69 PT, MV
Intraflagellar transport 122 homolog (Chlamydomonas) Ift122 2.66 MM, MV
H2-K region expressed gene 6 H2-Ke6 2.63 MM
Serine (or cysteine) peptidase inhibitor, clade F, member 1 Serpinf1 2.46 MM, MV
Zinc finger E-box binding homeobox 2 Zeb2 2.41 MM, MT, MV, PT, TR, TS
TSC22 domain family 3 Tsc22d3 2.37 MM
Zinc fingers and homeoboxes 1 Zhx1 2.37 DB, PT, TR
Heat shock protein 1A Hspa1a 2.35 MM
Kelch domain containing 8B Klhdc8b 2.32 MM
Runt-related transcription factor 1; translocated to 1 (cyclin D-related) Runx1t1 2.32 TS
Docking protein 4 Dok4 2.28 MT, MV, PT, TS, TR
Myosin VIIa Myo7a 2.26 MV
Retinoid X receptor beta Rxrb 2.23 MM
Glypican 2 (cerebroglycan) Gpc2 2.22 TS
Laminin, alpha 1 Lama1 2.22 MV
Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha II
polypeptide
P4ha2 2.17 MM
Ral guanine nucleotide dissociation stimulator-like 1 Rgl1 2.17 TR, MM
Abhydrolase domain containing 4 Abhd4 2.07 MV
Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1
polypeptide
P4ha1 2.06 DB, MM, TR
Data from Affymetrix microarray analysis of gene expression was used to identify targets of miR-205. Statistically significant (P 0.001) downregulated fold
change is the change in expression of transcripts from COMMA-D Geo cells overexpressing miR-205, relative to the Luciferase shRNA cells. Expression data
were compared with several publicly available algorithms: DB, miRDB (http://mirdb.org/miRDB/index.html); MM, miRNAMap (http://mirnamap.mbc.nctu.
edu.tw/); MV, miRNA Viewer using miRanda (http://cbio.mskcc.org/mirnaviewer/); MT, MicroT (http://diana.cslab.ece.ntua.gr/); PT, PicTar (http://pictar.mdc-
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miR-205 is highly expressed in mouse mammary-gland
stem-cell populations
Although the Sca-1+ population of the COMMA-DbGeo cell line
represents a subpopulation with basal cell characteristics retaining
stem- and progenitor-cell capabilities, this is quite different from
the Sca-1+ cells isolated from primary MECs, which are thought
to represent primarily a lumenal estrogen-receptor (ER)+ population.
For example, it was previously demonstrated that the virgin mouse
mammary gland has a basal cell population represented by a
Lin–CD24+/lo/Sca-1– profile that is enriched for mammary stem cells
(Sleeman et al., 2006), in addition to populations that are lumenal
ER– cells that are Lin–CD24+/hi/Sca-1– and lumenal ER+ cells that
are Lin–CD24+/hi/Sca-1+ (Sleeman et al., 2007) as well as a
Lin–CD24–/Sca-1+ non-epithelial population (Shackleton et al.,
2006; Sleeman et al., 2006; Stingl et al., 2006). Surprisingly, FACS
analysis demonstrated that the COMMA-DbGeo cell line is
essentially homogeneous for CD29+ and CD24+ expression
(supplementary material Fig. S3A). Thus, we sought to determine
how the results obtained for miR-205 expression in the COMMA-
DbGeo model compared with its expression in primary mammary
stem or progenitor cells. Accordingly, we used adult virgin Balb/c
female mammary glands to isolate MECs on the basis of the cell-
surface markers Sca-1, CD29 (b-1 integrin), CD24 (heat-stable
antigen) and CD49f (a6 integrin), which identifies populations that
are enriched in mammary-gland stem cells (Fig. 6A-E). When sorted
for these populations and assayed for miRNA expression, we
observed high expression of miR-205 in the populations that were
enriched for mammary-gland stem cells as well as myoepithelial
cell populations. The CD24/Sca-1 mammary-gland stem-cell-
enriched population (Lin–CD24+/lo/Sca-1–) (Fig. 6A) had
approximately 25-fold higher expression of miR-205 than the
lumenal ER– Lin–CD24+/hi/Sca-1– and lumenal ER+ Lin–CD24+/hi/
Sca-1+ populations, whereas the myoepithelial and basal
Lin–CD24+/lo/Sca-1+ population retained moderate expression of
miR-205 (Fig. 6B). Furthermore, profiling and characterization of
CD29/CD24 populations identified the Lin–CD29hi/CD24+
population as being enriched for slowly cycling mammary-gland
stem cells such that a single Lin–CD29hi/CD24+ cell was capable
of regenerating a mammary gland (Shackleton et al., 2006). This
Lin–CD29hi/CD24+ population, although enriched for mammary-
regenerating stem cells, also contains myoepithelial cells and is
mostly Sca-1– (Shackleton et al., 2006). As in the Lin–CD24+/lo/Sca-
1– stem-cell-enriched population, when mammary epithelial cells
were sorted for CD29/CD24 (Fig. 6C), we also observed high
expression, approximately 80-fold compared with other cell types,
of miR-205 in the mammary stem-cell-enriched Lin–CD29hi/CD24+
population (Fig. 6D). The methods of enriching for stem and
progenitor cells by isolating Lin–CD24+/lo/Sca-1– and Lin–CD29hi/
CD24+ cells results in populations containing a mix of myoepithelial,
basal and stem cells. To distinguish between myoepithelial cells
Fig 5. Targets of miR-205. (A,B,G-I) SYBR Green
qPCR of putative targets of miR-205; (C-E) TaqMan
qPCR of putative targets of miR-205. Data represent
the mean expression levels of two biological replicates
calculated by CT normalized to either endogenous
b-actin (A,B,G-I) or 18S rRNA (C-E), of two
independent experiments performed in triplicate.
(A-C)Atp1a1, Dok4 and ZEB2 are transcripts identified
by microarray analysis that decreased when miR-205
was overexpressed. These transcripts were also
predicted targets of miR-205 by several algorithms
(Table 2). (A)Atp1a (ATPase, Na+-K+ transporting, a1
polypeptide) expression is 1.78-fold lower in miR-205-
overexpressing cells (**P0.005) and is a predicted
miR-205 target by miRNAMap and miRNA Viewer.
(B)Dok4 expression is 2.28-fold lower in miR-205-
overexpressing cells (*P0.007) and is a predicted
miR-205 target by miRNA Viewer, TargetRank and
TargetScan. (C)ZEB2 expression is 2.41-fold lower in
miR-205-overexpressing cells (*P0.005) and is a
predicted miR-205 target by miRNAMap, TargetRank
and TargetScan. (D)ZEB1 expression is 1.7-fold in
miR-205-overexpressing cells (*P<0.05) and is a
predicted miR-205 target. (E)Expression of E-cadherin
increases 2.3-fold as a result of ZEB1 and ZEB2
decreasing following miR-205 overexpression
(***P0.0008). (F)Stably transduced COMMA-bGeo
cells were stained for E-caherin (green) and vimentin
(red). As a result of lower ZEB1 and ZEB2 expression
following miR-205 overexpression, membrane-bound
E-cadherin is upregulated. Some membrane-bound E-
cadherin can be detected in cells expressing the
luciferase shRNA, but only at areas of cell-cell
junctions (inset). Scale bars: 25m. (G-I)Six5, Ppp2r4 and Tcp1 expression levels decrease when miR-205 is overexpressed; however they are not predicted miR-
205 targets by any of the available algorithms. (G)Six5 (Six5 sine oculis-related homeobox 5 homolog) expression is 1.94-fold lower in miR-205-overexpressing
cells (***P0.009). (H)Ppp2r4 (protein phosphatase 2A, regulatory subunit B) expression is 1.46-fold lower in miR-205-overexpressing cells (*P0.004). (I)Tcp1












and mammary epithelial stem cells, we also isolated cells on the
basis of CD24/CD49f populations. Independent enrichment for
mammary-gland stem cells using CD24/CD49f allows the isolation
of a small population, referred to as the mammary repopulating units
(MRUs), characterized as Lin–CD24med/CD49fhi, which is
distinguished from the myoepithelial (MYO) Lin–CD24lo/CD49flo
population. MRUs are enriched for stem cells capable of repopulating
the mammary gland (Stingl et al., 2006). Again, when sorted for
CD24/CD49f (Fig. 6E) and assayed for miR-205 expression, we
observed a 30-fold increase in expression in the MRU population
compared with non-epithelial cells, and additionally we observed
high expression of miR-205 in the MYO population (Fig. 6F). Recent
studies using in situ hybridization on normal and mammary tumor
tissue samples found that miR-205 expression was restricted to the
myoepithelial cell layer, which contains both myoepithelial cells and
basal stem cells (Sempere et al., 2007), so the high expression of
miR-205 that we observed in the MYO and Lin–CD24+/lo/Sca-1+ is
consistent with these observations.
Because it has been reported that miR-205 and the members of
the miR-200 family might have overlapping functions in the
regulation of EMT via ZEB1 and ZEB2 (Gregory et al., 2008), we
assayed miRNA expression for members of the miR-200 family in
these stem-cell-enriched populations. We found that members of
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the miR-200 family were expressed in the K18+ lumenal stem-cell-
enriched Lin–CD29lo/CD24+ population (supplementary material
Fig. S3B) but we did not observe significantly decreased expression
in the Lin–CD29hi/CD24+ mammary stem-cell-enriched population.
We also observed expression of miR-200-family members in the
lumenal Lin–CD24+/hi/Sca-1– and the Lin–CD24+/hi/Sca-1+
populations, but not in the stem-cell-enriched Lin–CD24+/lo/Sca-1–
(supplementary material Fig. S3C). This is consistent with recent
findings that members of the miR-200 family are expressed at
significantly lower levels in the MRU population relative to the
colony-forming Ma-CFC population (Shimono et al., 2009).
Additionally, as we previously observed by microarray analysis,
miR-200b is expressed at lower levels in the Sca-1+ population
compared with the Sca-1– population of the COMMA-DbGeo cells
by miRNA analysis (Table 1) (supplementary material Fig. S3D).
Importantly, these results suggest that miR-205 and members of
the miR-200 family have unique functions and are not functionally
redundant. Furthermore, miR-205 seems to display elevated
expression in mammary MRUs in comparison to other
subpopulations, which contrasts what has been reported for miR-
200-family members. Thus, the identification of unique miR-205
targets in the current studies might help provide some insights into
the selective effects of these miRNAs in stem and progenitor cells.
Fig 6. miR-205 is highly expressed in mouse mammary-
gland stem-cell populations. Primary mammary epithelial
cells were isolated from wild-type Balb/c virgin females, age
8-9 weeks, and separated by FACS for cell-surface markers
and analyzed by TaqMan qPCR for miR-205 expression. Data
represent the mean expression levels of two different
biological replicates calculated by CT normalized to the
endogenous snoRNA55 control, of two independent
experiments performed in triplicate. (A)Representative FACS
profile for CD24-FITC and Sca-1–PE. (B)Cells from different
CD24/Sca-1 subpopulations were collected and assayed for
expression of miR-205. In the basal and myoepithelial
Lin–/CD24+/lo/Sca-1– stem-cell-enriched population, miR-205
expression is approximately 25-fold higher than in the lumenal
Lin–/CD24+/hi/Sca-1+ and Lin–/CD24+/hi/Sca-1– populations.
(C)Representative FACS profile for CD29-FITC and CD24-
PE. (D)Cells from different CD29/CD24 subpopulations were
collected and assayed for expression of miR-205. In the
Lin–/CD29hi/CD24+ self-renewing stem-cell-enriched
population, miR-205 expression is approximately 85-fold
higher than in the non-stem-cell populations, including the
lumenal progenitor Lin–/CD29lo/CD24+ population.
(E)Representative FACS profile for CD24-PE and CD49f-
FITC. (F)Cells from different CD24/CD49f subpopulations
were collected and assayed for expression of miR-205. In the
stem-cell-enriched MRU population (Lin–/CD24med/CD49fhi),
miR-205 expression is approximately 45-fold higher, and the
myoepithelial MYO population (Lin–/CD24lo/CD49flo) is
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Discussion
When aberrantly expressed, either by deletions associated with
frequent fragile sites or genomic amplification, miRNAs play an
important role in carcinogenesis (Bartel, 2004; Calin et al., 2004;
He et al., 2005; Kluiver et al., 2006) and accordingly are thought
to represent crucial cancer biomarkers. In previous studies
comparing miRNA expression with ER/progesterone-receptor
(PR)/ErbB2 status in human breast cancers, miR-205 upregulation
was shown to correlate with ER+/PR+ breast tumors (as compared
to ER–/PR– tumors) but it did not show a significant correlation
with ErbB2+ status (Mattie et al., 2006). In addition to breast cancers,
miR-205 has been shown to be overexpressed in head and neck
cancer cell lines (Jiang et al., 2005), and in cervical (Wang et al.,
2008), bladder (Gottardo et al., 2007) and non-small cell lung
(Markou et al., 2008) cancers, as compared with normal tissues.
Additionally, miR-205 has been shown to regulate the process of
EMT by means of silencing ZEB2 and ZEB1, a repressor of E-
cadherin and regulator of EMT, as discussed previously.
Interestingly, an association between low miR-205 expression in
the myoepithelial and basal cells of ER–/PR–/Her2– basal breast
cancer patient samples has been correlated with tumor progression
(Sempere et al., 2007), possibly owing to its regulation of EMT via
ZEB1 and ZEB2. High levels of miR-205 have also been observed
in normal lobular and ductal mammary myoepithelial cells,
implicating a potential role in normal development (Sempere et al.,
2007).
In the COMMA-DbGeo cells overexpressing miR-205, we
observed a significant 10-15% expansion of the Sca-1+ cell
population. This is consistent with several previous observations
that loss of PTEN leads to an expansion of stem cells. Loss of PTEN
has been associated with stem-cell expansion of Flk-2–Sca-1+Lin–c-
Kit+CD48– hematopoietic stem cells (Yilmaz et al., 2006), as well
as expansion of the Sca-1+/BCL-2+ basal stem cells and progenitors
in the prostate (Wang et al., 2006). Our results also indicated that
miR-205 overexpression led to increased proliferation. This
recapitulates other findings that loss of PTEN results in increased
cell proliferation by regulating cell-cycle entry (Groszer et al., 2006).
However, our observed decrease in cell size following
overexpression of miR-205 has not been shown in other PTEN loss-
of-function studies, although this effect is probably cell-type
dependent as loss-of-function studies demonstrate a variety of
phenotypes (reviewed in Knobbe et al., 2008). Thus, although PTEN
might play a role in some of the phenotypes caused by miR-205
overexpression, there must be other targets involved. Cell size is
controlled by the cell cycle and the process of S-phase initiation,
which depends on the concentration of extracellular growth factors.
It is of note that IPA determined that both cellular-growth and cell-
morphology pathways are significantly affected by miR-205
overexpression. The genes involved in these pathways might give
insight into the observed 4-9% decrease in cell size and increased
proliferation following miR-205 overexpression. Additionally, it has
been observed that cell size increased when normal mouse
mammary epithelial cells were induced by TGFb to undergo EMT,
compared with untreated cells (Lamouille and Derynck, 2007).
Thus, keeping cells in a more epithelial-like state by overexpressing
miR-205 might be the cause of the decreased cell size we observed.
Additionally, miR-205 overexpression by nearly fivefold in Sca-1–
cells resulted in a gain in the ability of these cells to form colonies
on Matrigel. Although this increase in expression is significant
compared with the luciferase shRNA Sca-1– cells, this level of
expression was not as high as that found in Sca-1+ cells. Although
the number of colonies formed from the miR-205-overexpressing
Sca-1– cells was significantly smaller than the number of colonies
observed in Sca-1+ cells, this finding might indicate that, although
expression of miR-205 might contribute to a gain of growth
potential, expression of miR-205 alone does not seem to be
sufficient to confer self-renewal to a non-progenitor cell population.
Two recent reports have identified new targets of miR-205.
Protein kinase Ce was identified as a miR-205 target in prostate
cells (Gandellini et al., 2009) and ErbB3 (also known as HER3)
was shown to be a miR-205 target in breast cancer cells (Iorio et
al., 2009). These studies indicated that, in both prostate cancer and
breast cancer cells, miR-205 overexpression led to tumor-suppressor
activity by reduction of cell migration and regulation of EMT, and
inhibition of cell growth and increased sensitivity to anti-cancer
agents. These studies demonstrated that overexpression of miR-205
also led to the decrease in phospho-ERK and phospho-AKT levels,
both of which are also downstream of the PI3K pathway. We also
observed a decrease in levels of phospho-AKT and phospho-ERK
in our miR-205-overexpressing cells compared with the control,
despite downregulation of PTEN (supplementary material Fig. S4).
The different effect of miR-205 on cell growth might be due to the
fact that these studies were performed in transformed cancer cell
lines, whereas ours used normal epithelial cells. Thus, the high levels
of expression of miR-205 found in both normal mammary
myoepithelial and stem cells, as well as in cancer cells, might
indicate its involvement in early cancer lesions.
To further investigate other targets of miR-205, we analyzed the
potential for miR-205 to regulate other mRNAs genome-wide.
These studies demonstrated that two recently identified targets of
miR-205, ZEB1 and ZEB2, are also regulated in the COMMA-
DbGeo epithelial cells. In addition to PTEN, ZEB1 and ZEB2, we
have identified 45 putative targets of miR-205 that were predicted
by several target prediction algorithms. Of the confirmed predicted
targets, we demonstrated decreased mRNA levels of Atpa1a1 and
Dok4 in association with overexpression of miR-205, in addition
to several non-predicted targets. Although there were many potential
targets identified by our array analysis, we found overlaps with gene
sets associated with stem-cell differentiation pathways. Owing to
the potential of miR-205 to regulate so many different mRNAs, the
phenotypes associated with miR-205 overexpression are probably
due to pleitropic effects on multiple gene targets and probably will
depend on the cell context. This is also probable, because gene
expression arrays usually underestimate the total number of miRNA
targets, many of which might only be detected at the protein level
(Baek et al., 2008).
Several groups have recently described enrichment strategies for
mammary-gland stem and progenitor cells. Using cell-surface
markers, Stingl et al. identified the MRU (CD24med/CD49f hi)
epithelial-cell population as enriched for stem and progenitor cells
with in vivo regenerative potential, whereas the MYO
(CD24lo/CD49f lo) population was enriched for K14+ and a-SMA-
expressing cells (Stingl et al., 2006). Interestingly, although the
MRU population has low expression of miR-200-family members
(Shimono et al., 2009), this population has high miR-205 expression,
suggesting that other targets besides ZEB1 and ZEB2 are probably
playing crucial roles in their unique functions. Shackleton et al.
identified a cell population characterized by the Lin–CD29hi/CD24+
profile that was enriched for K14+ cells and had similar stem- and
progenitor-cell capabilities (Shackleton et al., 2006). Furthermore,
Sleeman et al. used the CD24lo/CD49f hi/Sca-1– population to
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for Sca-1+/hi cells from these primary MECs did not retain stem
and progenitor activity, and there was no enrichment for Sca-1 in
the CD24med/CD49f hi or CD29hi/CD24+ stem-cell-enriched
populations (Shackleton et al., 2006; Stingl et al., 2006), in contrast
to the COMMA-DbGeo cell line and primary MECs grown in
culture (Chen et al., 2007; Deugnier et al., 2006; Welm et al., 2002;
Woodward et al., 2007). In fact, when freshly isolated MECs were
grown in culture, Sca-1 expression was significantly upregulated,
but there was no significant change in CD24 or CD49f expression
(Matulka et al., 2007). The reasons for this discrepancy between a
cell-line model and primary MECs are not apparent, but might
reflect changes in Sca-1 expression reported to occur as a function
of cell culture that has been observed by several groups (Matulka
et al., 2007; Shackleton et al., 2006; Stingl et al., 2006). The precise
genetic events that led to the immortalization of the COMMA-
DbGeo cells are not known, but use of this model did facilitate the
identification of miR-205 in the Sca-1+ population, which correlated
with the high expression of miR-205 in MRUs and other populations
enriched for mammary-gland stem and progenitor cells. Although
miR-205 is frequently overexpressed in cancer compared with
normal tissues, it has also been observed to be highly expressed in
normal tissue (Volinia et al., 2006). This miRNA might not only
be involved in normal cell function (proliferation, differentiation
and growth), but its mis-regulation might contribute to cancer
initiation, progression and metastasis. These current studies also
suggest that miR-205 overexpression might affect progenitor-cell
expansion, which might be important in the etiology of cancer.
Generation of loss-of-function mouse models for miR-205 will be
required to establish whether miR-205 is essential for normal
development. Overexpression and loss-of-function mouse models
would also allow for studies to determine the effect of miR-205
specifically on mammary stem cells. Additionally, generating miR-
205-overexpression and loss-of-function mouse cancer models
might demonstrate the mechanisms by which miR-205 mis-
regulation contributes to cancer initiation and progression.
Materials and Methods
Cell lines
The COMMA-DbGeo cell line passages 21-27 was kindly provided by Daniel Medina
at Baylor College of Medicine, Houston, TX. The cells were grown in DMEM/F12
(Invitrogen) at pH 7.6, with 2% adult bovine serum (ABS) (Gemini Bioproducts), 5
g/ml gentamycin (Sigma), 10 g/ml insulin (Invitrogen) and 5 ng/ml EGF
(Invitrogen) in a 5% CO2 humidified chamber. NIH/3T3 cells were purchased from
ATCC and cultured in DMEM (Invitrogen) with 10% bovine calf serum (BCS) (SAFC
Biosciences) in a 5% CO2 humidified chamber. 293T cells were purchased from ATCC
and maintained in DMEM with 10% fetal bovine serum (FBS) (SAFC Biosciences)
in a 5% CO2 humidified chamber.
Custom miRNA microarrays
Total RNA (10 g) purified from Sca-1+ and Sca-1– cells isolated by FACS was
hybridized to custom miRNA microarrays as previously described (Thomson et al.,
2004). Array analysis was performed with dChip (Li and Wong, 2001) and WebArray
(Xia et al., 2005).
Paraflo miRNA microarray
This microarray assay was performed using a service provider (LC Sciences) through
a custom array, as previously described (Gu et al., 2008). Custom microarrays were
spotted with all of the mature miRNA sequences in miRBase at the time of assembly,
approximately 200 probes, whereas Paraflo microarrays contained 328 human and
approximately 300 mouse miRNAs, plus 2000 computationally predicted miRNA
sequences from human and mouse.
Construction of pSHAG-MAGIC2c miRNA overexpression vectors
The endogenous mouse stem-loop pre-miR-205 sequence was obtained from miRBase.
Oligonucleotides containing the full pre-miRNA sequence were synthesized, PCR
amplified and TA cloned into pCR-2.1 TOPO (Invitrogen). Stem-loop sequences were
subsequently verified by sequencing and subcloned into the XhoI-EcoRI site of the
pSHAG-MAGIC2c (pSM2) vector (Open Biosystems) (Paddison et al., 2004). As
non-miRNA controls, plasmids expressing an shRNA targeting the firefly luciferase
cDNA (pSM2-luciferase shRNA RHS1705, Open Biosystems), as well as a non-
silencing hairpin control (pSM2-NShp RHS1707, Open Biosystems), were used, in
addition to a PTEN shRNA (RHS1764-9209859, Open Biosystems).
Retroviral transduction
COMMA-DbGeo cells
Passage 8 293T-packaging cells were transiently transfected with pSM2-miRNA
vectors and pCL-Eco (Imgenex) using FuGENE 6 (Roche) according to the
manufacturer’s guidelines. Forty-eight hours after transfection (day 3),
virus-containing medium was collected from transfected 293T cells, filtered through
a 0.45-m syringe filter, and applied to passage 20 COMMA-DbGeo with the addition
of 10 mM HEPES (Invitrogen) and 5 mg/ml polybrene (Millipore). The cells were
spun at 300 g in a swinging platform rotor for 30 minutes. After spinning, the retroviral
supernatant was removed from COMMA-DbGeo cells and replaced with fresh
medium. Forty-eight hours later, cells were trypsinized and split at a low density with
the addition of 2 g/ml puromycin (Sigma) to select for transduced cells.
NIH/3T3 cells
Transduction was performed on passage 9 NIH/3T3 cells as for the COMMA-DbGeo
cells with the exception of the spin. Instead, cells were left with the virus-containing
medium overnight and replaced with fresh medium 12 hours later.
Colony-forming assay
Retrovirally transduced COMMA-DbGeo were cells prepared for flow cytometry
using an anti-Ly6A/E (Sca-1) antibody conjugated to FITC (BD Pharmingen). Cells
were incubated with Sca-1 antibody for 15 minutes on ice, resuspended in HBSS+
[HBSS (Invitrogen), 2% FBS and 100 mM HEPES], and filtered through a 40-m
cell filter into polypropylene tubes containing 0.5 g/ml propidium iodide (Sigma)
to exclude dead cells. Analysis and sorting were performed on a triple laser MoFlo
(Dako-Cytomation). Data analysis was performed on FlowJo version 8 (Tree Star).
500 cells per well were sorted as either Sca-1+ or Sca-1– into round-bottom 96-well
plates containing 30 l Matrigel Basement Membrane Matrix (BD Biosciences). After
sorting, 100 l of COMMA-DbGeo medium was added to each well and plates were
incubated for 8 days. Plates were then fixed in glacial acetic acid and methanol (1:2;
10 minutes) and stained with crystal violet. Colonies were counted with ImageJ
software.
Cell-proliferation assays
Cells were plated at 50,000 cells/plate in 60-mm plates and replenished with fresh
media every 48 hours. Cells were trypsinized and counted every 24 hours for 6 days
using a Vi-CELL XR Cell Viability Analyzer (Beckman Coulter) for a growth curve.
For the proliferation assay, cells were trypsinized every 48 hours for 6 days and
proliferation was determined using the Click-iT EdU Flow Cytometry Assay Kit
(Invitrogen) with PI incorporation, and analyzed on an LSRII (BD Biosciences).
miRNA real-time RT-PCR
Total RNA was isolated using miRNeasy (Qiagen) and cDNA was synthesized from
10 ng of total RNA using the TaqMan MicroRNA Reverse Transcription Kit with
miRNA-specific RT primer from the TaqMan MicroRNA Assay Mix. miRNA levels
were measured using the miRNA-specific TaqMan probe provided in the MicroRNA
Assays and the TaqMan Gene Expression Maser Mix (Applied Biosystems).
Experiments were performed in triplicate. miRNA levels were normalized to
snoRNA55 (Applied Biosystems) and fold change was determined by the comparative
threshold method (DDCT).
mRNA real-time RT-PCR
Total RNA was isolated from cells using miRNeasy (Qiagen). cDNA was made from
1 g of total RNA with SuperScript II (Invitrogen) using random primers. cDNA
was then treated with RNase H (Invitrogen) to remove RNA. For SYBR Green qPCR,
amplification of cDNA was performed with SYBR Green PCR Maser Mix (Applied
Biosystems), and normalized to b-actin. For TaqMan qPCR, amplification of cDNA
was performed with TaqMan Gene Expression Maser Mix. Gene Expression Assays
for PTEN and 18S rRNA were used (Applied Biosystems), in addition to custom
PrimeTime TaqMan probe/primer sets for ZEB1, ZEB2 and E-cadherin (Integrated
DNA Technologies). All qPCR was performed using the StepOnePlus Real-Time
PCR System and software (Applied Biosystems). mRNA levels are shown as relative
to 18S. Primer sets for qPCR are detailed in supplementary material Table S2.
Lentiviral miRNA inhibition
A lentiviral-based anti-miRNA expression vector, pmiRZip-205, was obtained from
System Biosciences and used to stably transduce NIH/3T3 cells as per manufacturer
recommendations. As a control, the luciferase shRNA was cloned from the pSM2-
LucshRNA vector into the BamHI-EcoRI site of the pmiRZip vector (pmiRZip Luc
shRNA).
Luciferase assay
The pGL3-PTEN 3UTR plasmid was constructed with the 2.7 kb 3UTR of PTEN
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2.1 TOPO (Invitrogen), sequence verified and subcloned into the XbaI site of the
pGL3-promoter vector (Promega). Stably transduced NIH/3T3 were co-transfected
with pRL-null Renilla luciferase control (Promega) and pGL3-PTEN 3UTR luciferase
reporter plasmids (200 ng each) with FuGENE 6 transfection reagent (Roche) as per
the manufacturer’s protocol. Luciferase activity was measured 48 hours post-
transfection with the Dual Luciferase Reporter Assay System (Promega) and reported
as relative luciferase units (firefly luciferase/Renilla luciferase). miRNA-target-site
mutants were generated with the Stratagene QuikChange II XL Site-Directed
Mutagenesis Kit and sequence verified.
Western blotting
Cells were lysed in RIPA buffer with protease and phosphatase inhibitors (Roche).
The protein concentration was assayed by BCA (Bio-Rad) and 25 g of protein was
separated on a 12% SDS-PAGE gel, transferred onto PVDF membrane and blotted
with an anti-PTEN antibody (Santa Cruz Biotechnology), anti-phospho-GSK-3b
(Ser9) and total GSK-3b (Cell Signaling) antibodies. The blot was stripped and
reprobed with an anti-b-actin antibody (Sigma) or an anti-GAPDH antibody (AbD
Serotech). Autoradiographic images were quantitated using ImageJ (Abramoff et al.,
2004).
Immunofluorescence
Stably transduced cell lines were grown on poly-D-lysine-coated coverslips, fixed
with 4% PFA for 15 minutes, followed by methanol permeabilization for 20 minutes
at –20°C, then blocked using the M.O.M. Basic Kit (Vector Laboratories). Cells were
stained with anti-E-cadherin (1:50) (BD Biosciences) and anti-vimentin (1:250)
(Fitzgerald Industries) primary antibodies, and anti-mouse IgG–Alexa-Fluor-488
(1:100) and anti-guinea-pig IgG–Alexa-Fluor-594 (1:100) (Invitrogen) secondary
antibodies. Coverslips were mounted with VECTASHIELD Mounting Medium with
DAPI (Vector Laboratories).
Primary mammary epithelial cell preparations
Mouse mammary-gland cells were prepared as previously described (Zhang et al.,
2008b) from 8- to 9-week-old Balb/c mice. Cells were labeled with antibodies for
cell-surface markers: Sca-1-PE (1:300), CD29-FITC (1:200), CD24-PE (1:100),
CD-24-FITC (1:200), CD49f-FITC (1:500) and separated by FACS using a BD
FACSAria II cell sorter. Dead cells were excluded by Sytox Red (Invitrogen) and
non-epithelial lineage-positive cells were excluded using a biotin-conjugated mouse
lineage panel kit containing antibodies against CD3e, CD11b, CD45R/B220,
Ly-6G/C and TER-119 (BD Bioscience), in addition to biotin-conjugated CD31 and
CD140a antibodies.
miRNA SYBR Green qPCR
miRNA SYBR Green qPCR was performed as described previously (Shi and Chiang,
2005). Total RNA was isolated from cells with RNA-Bee (Tel-Test) and treated with
DNaseI (Invitrogen). Total RNA (1 µg) was polyadenylated with Escherichia coli
poly(A) polymerase (Ambion). Unincorporated nucleotides were removed by column
purification using ChromaSpin-30 (BD Biosciences) columns. cDNA was transcribed
with SuperScript II (Invitrogen) using a miRNA RT gene-specific primer. cDNA was
then treated with RNase H (Invitrogen) to remove RNA. Amplification was performed
with FastStart SYBR Green Master Mix (Rox) (Roche) using the ABI 7500 (Applied
Biosystems). Primer sets for miRNA SYBR Green qPCR were obtained from Jiang
et al. (Jiang et al., 2005).
Statistical analysis
Statistical significance was analyzed by unpaired Student’s t-test, and P≤0.05 was
considered to be statistically significant. All data are represented as the mean ± s.e.m.
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